...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Tropical Medicine and Hygiene >Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony.
【24h】

Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony.

机译：己酮可可碱加锑成功治疗难治性粘膜利什曼病。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Mucosal leishmaniasis is characterized by an intense inflammatory reaction and tissue damage with few parasites in the lesion. On the basis of previous observations that suggest a possible role of tumor necrosis factor alpha (TNF-alpha) in the pathology of this disease, an open-label study was performed to evaluate the efficacy of the treatment with an inhibitor of TNF-alpha (pentoxifylline) associated to antimony therapy in 10 patients with refractory mucosal leishmaniasis. Patients were treated with pentavalent antimony (20 mg per kilogram of body weight per day) plus orally administered pentoxifylline 400 mg 3 times daily for 30 days. Nine of 10 patients fulfilled the criteria for cure: they experienced complete reepithelization of the mucosal tissue 90 days after therapy and displayed no evidence of relapse at 1 year of follow-up. The TNF-alpha levels before therapy (776 +/- 342 pg/mL) fell to 94 +/- 57 pg/mL (P < 0.05) within 60 days after therapy. Our results indicate that pentoxifylline plus antimony therapy should be considered in all patients with mucosal leishmaniasis that is refractory to treatment.
机译：粘膜利什曼病的特征在于强烈的炎症反应和组织损伤，病灶中很少有寄生虫。根据先前的观察结果，提示肿瘤坏死因子α（TNF-alpha）在该疾病的病理过程中可能发挥作用，进行了一项开放标签研究，以评估使用TNF-α抑制剂治疗的疗效（己酮可可碱与锑治疗相关的10例难治性粘膜利什曼病患者。患者接受五价锑（每天每公斤体重20毫克）加口服己酮可可碱400毫克每天3次，共30天。 10名患者中有9名符合治愈标准：治疗后90天，他们经历了粘膜组织的完全再上皮化，并且在随访的1年内未显示复发的迹象。治疗后60天内，治疗前的TNF-α水平（776 +/- 342 pg / mL）降至94 +/- 57 pg / mL（P <0.05）。我们的结果表明，对所有难治性粘膜利什曼病的患者应考虑使用己酮可可碱加锑治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号